Waldencast Acquires Novaestiq Corp. from Gore Range Capital

Waldencast plc has agreed to acquire Novaestiq Corp., enhancing Obagi Medical's product range with innovative injectable hyaluronic gels. These include Saypha® ChIQ™ and Saypha® MagIQ™, developed with Croma-Pharma GmbH. Obagi Medical will introduce this line, known for blending potent skincare with professional procedures.

This acquisition highlights the demand for advanced skin solutions. The combination of Obagi's reputation and Novaestiq's expertise promises to transform aesthetic skincare, offering science-backed solutions. Gore Range Capital sees this as a significant step, reflecting their commitment to innovation and patient safety.

Saypha®, already used globally, awaits FDA approval. Waldencast's acquisition involves cash, royalties, and potential shares based on achieving sales milestones. The move aligns with Waldencast's strategy to expand its beauty and wellness portfolio.